Trial Profile
An Open-label, Randomized, Five Period Crossover Study to Estimate the Relative Bioavailability of Five Formulations of 400 mg Ronacaleret (a Calcium-sensing Receptor Antagonist) Administered as a Single Oral Dose to Healthy Postmenopausal Females
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Ronacaleret (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 23 Apr 2008 New trial record.